PROTACs to RIPTACs: Arvinas founder snags $76M for next bet, Halda Therapeutics
A leader in the protein degradation space, Yale’s Craig Crews, is back with another biotech, Halda Therapeutics.
On Tuesday, the startup announced $76 million in funding to take forward a new technology out of Crews’ lab, called RIPTACs, or Regulated Induced Proximity TArgeting Chimeras.
The 26-employee startup emerged from his decades-long work on heterobifunctional molecules, he told Endpoints News, dating back to his 2001 paper on PROTACs, which formed the foundation for Arvinas in 2013.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.